Next week, June 21-26, stem cell biotechnology company Asymmetrex will participate as a presenter and an exhibitor in the 2021 Annual Meeting of the International Society for Stem Cell Research. In an invited poster presentation (#345) and a company exhibitor display, Asymmetrex will introduce the virtual gathering of international stem cell scientists, physicians, and biotechnologists to
In a June 11 posting, online business and technology news portal SuperbCrew reported their recent interview with Asymmetrex President and CEO James L. Sherley, M.D., Ph.D. about the company’s upcoming first participation in an annual meeting of the International Society for Stem Cell Research. Asymmetrex’s exhibitor display and research poster #345 presentation in the virtual
Today, May 20, in the virtual 5th Annual MarketsandMarkets Bioprocessing of Biotherapeutics Conference, the President and CEO of stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., introduced company executives and scientists to new technologies for determining the dosage of therapeutic stem cell products and treatments. A Gold Sponsor for the conference, Asymmetrex’s kinetic
Today, May 11, in the Clinical Trial Supply USA 2021 – Virtual Conference, the President and CEO of stem cell biotechnology company Asymmetrex, James L. Sherley, M.D., Ph.D., discussed new developments on the horizon for the supply chains for stem cell therapy and gene therapy clinical trials. In particular, he suggested that it is inevitable
During the coming months of May and June, stem cell biotechnology company Asymmetrex is invited to give presentations in several different virtual conferences that span the fields of clinical trial supply, cell biotherapeutics, stem cell science, and stem cell medicine. The company’s relevance to these diverse disciplines reflects the broad scope of the impact of
On March 24, in Arena International’s 2021 Virtual Conference on Clinical Trial Supply-Europe, stem cell biotechnology company Asymmetrex described emerging technologies that will end a critical knowledge gap in the supply chain for stem cell clinical trials. Asymmetrex CEO, James L. Sherley, discussed how the effectiveness of the supply chain will improve with the introduction
Asymmetrex’s latest research report verifying the presence of immortal DNA strands in human tissue stem cells was featured by Kerafast. While other reports have verified immortal DNA strands in stem cells in species such as mold, plants, insects and mice, Asymmetrex’s new study is the first to describe the occurrence of immortal DNA strands in
Superb Crew interviewed Asymmetrex Director James Sherley to discuss the latest Asymmetrex report of a new advance on stem cell immortality. This interview goes into detail about how stem cell immortality is connected with kinetic stem cell counting, how it will impact the future of kinetic stem cell counting technology, and Asymmetrex’s connection to this
Asymmetrex has partnered with Proventa International to provide an online workshop on kinetic tissue stem cell counting for better medicine through counting stem cells to improve regenerative and pharmaceutical medicines. The online workshop is on February 18, 2021 at 11AM PST / 2PM EST. In 2020, the FDA’s Standards Coordinating Body (SCB) identified specific counting
On November 13, stem cell biotechnology company Asymmetrex published a seminal research report confirming the presence of immortal DNA strands in human tissue stem cells. Immortal DNA strands are the molecular basis for the immortality of tissue stem cells. What does it mean for multiplying cells in the body to be immortal? The cell DNA